Education
About Us
Working with TipRanks
Follow Us
Enovis Corporation (ENOV)
:ENOV
ENOV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.47 - $49.83
Previous CloseN/A
Volume391.51K
Average Volume (3M)1.07M
Market Cap
$1.85B
Enterprise Value$3.35B
Total Cash (Recent Filing)$44.07M
Total Debt (Recent Filing)$1.46B
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Oct 30, 2025EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.79
Shares Outstanding57,159,800
10 Day Avg. Volume1,034,880
30 Day Avg. Volume1,072,136
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio-36.09
Enterprise Value/Market Cap1.81
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit2.57
Enterprise Value/Ebitda-7.27
Forecast
1Y Price Target
$51.00Price Target Upside57.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Financial GuidanceENOV raised its FY25 guidance across revenue, organic growth, EBITDA, and EPS, supported by operational execution, FX tailwinds, and decreased expected tariff impacts.
Product LaunchENOV is advancing its enabling tech strategy with the next-gen ARVIS launch, featuring enhancements that have generated strong enthusiasm from surgeons.
ValuationThe stock is trading at less than half the valuation of its mid-cap MedTech peers, suggesting it is significantly undervalued.
Bears Say
Product Launch DelayThe next-gen ARVIS launch has been delayed by approximately 6 months to incorporate enhancements, although surgeon excitement around the platform remains high.
Recon Segment WeaknessThere seem to be some pockets of recon weakness like flat hip/knee growth, in part due to the delayed launch of Arvis.
Revenue GrowthOrganic revenue growth slowed to 5.1% in 2Q25 from 10.4% in 1Q25.
Enovis News
ENOV FAQ
What was Enovis Corporation’s price range in the past 12 months?
Enovis Corporation lowest stock price was $25.46 and its highest was $49.83 in the past 12 months.
What is Enovis Corporation’s market cap?
Enovis Corporation’s market cap is $1.85B.
When is Enovis Corporation’s upcoming earnings report date?
Enovis Corporation’s upcoming earnings report date is Oct 30, 2025 which is in 39 days.
How were Enovis Corporation’s earnings last quarter?
Enovis Corporation released its earnings results on Aug 07, 2025. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.719 by $0.071.
Is Enovis Corporation overvalued?
According to Wall Street analysts Enovis Corporation’s price is currently Undervalued.
Does Enovis Corporation pay dividends?
Enovis Corporation does not currently pay dividends.
What is Enovis Corporation’s EPS estimate?
Enovis Corporation’s EPS estimate is 0.65.
How many shares outstanding does Enovis Corporation have?
Enovis Corporation has 57,159,800 shares outstanding.
What happened to Enovis Corporation’s price movement after its last earnings report?
Enovis Corporation reported an EPS of $0.79 in its last earnings report, beating expectations of $0.719. Following the earnings report the stock price went up 10.714%.
Which hedge fund is a major shareholder of Enovis Corporation?
Currently, no hedge funds are holding shares in ENOV
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.00 (57.60% Upside)
$51.00 (57.60% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $663.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 40.4%
Last 30 Days ▲ 40.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.12%
12-Months-Change
Fundamentals
Return on Equity
-28.31%
Trailing 12-Months
Asset Growth
-7.73%
Trailing 12-Months
Company Description
Enovis Corporation
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
ENOV Company Deck
ENOV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Enovis was generally positive, with strong revenue and margin growth, successful product launches, and improved financial guidance. However, there were challenges such as delays in the Arvis product launch, flat growth in the U.S. hip and knee segment, and tariff-related headwinds. Despite these setbacks, the company's overall performance and outlook are optimistic.View all ENOV earnings summariesENOV Stock 12 Month Forecast
Average Price Target
$51.00
▲(57.60% Upside)
Technical Analysis
Enerpac Tool Group
―
Hillenbrand
―
Standex International
―
Helios Technologies
―
Xometry
―
Ownership Overview
2.12% Insiders
45.74% Mutual Funds
0.64% Other Institutional Investors
21.80% Public Companies and
Individual Investors